Author Archives: George MacDonald

Viemed Healthcare (VMD) Gets a Buy Rating from Acumen Capital

In a report issued on August 4, Nick Corcoran from Acumen Capital reiterated a Buy rating on Viemed Healthcare (NASDAQ: VMD), with a price target of C$14.00. The company’s shares closed last Thursday at $6.00. The word on The Street

Canaccord Genuity Thinks B2Gold’s Stock is Going to Recover

Canaccord Genuity analyst Carey MacRury reiterated a Buy rating on B2Gold (NYSE MKT: BTG) on August 6 and set a price target of C$9.50. The company’s shares closed last Wednesday at $3.85, close to its 52-week low of $3.65. B2Gold

Lake Street Reiterates Buy on Realnetworks Shares, Sees 245% Upside For The Stock

In a research report published on Thursday, Lake Street analyst Mark Argento reiterated a Buy rating on Realnetworks (NASDAQ:RNWK)with a price target of $6, which implies an upside of 245% from current levels. According to TipRanks.com, which measures analysts’ and

Oppenheimer Sticks to Its Outperform Rating for Humanigen (HGEN)

Oppenheimer analyst Kevin DeGeeter reiterated an Outperform rating on Humanigen (NASDAQ: HGEN) on August 2 and set a price target of $30.00. The company’s shares closed last Wednesday at $16.00. Currently, the analyst consensus on Humanigen is a Strong Buy

Raymond James Reiterates Their Buy Rating on NexPoint Real Estate ate Finance (NREF)

In a report issued on June 29, Stephen Laws from Raymond James reiterated a Buy rating on NexPoint Real Estate ate Finance (NYSE: NREF), with a price target of $22.50. The company’s shares closed last Monday at $19.69. The word

Ouster (OUST) Receives a Buy from Craig-Hallum

Craig-Hallum analyst Richard Shannon reiterated a Buy rating on Ouster (NYSE: OUST) on June 22 and set a price target of $20.00. The company’s shares closed last Monday at $9.08. Currently, the analyst consensus on Ouster is a Strong Buy